Seroatlas · Human Serome Atlas

PRAME

Melanoma antigen preferentially expressed in tumors

Also known as: CT130, MAPE, PRAME_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P78395
Gene
PRAME
Ensembl
ENSG00000185686
Chromosome
22
Canonical length
509 aa
Protein class
Plasma proteins, Predicted intracellular proteins
Subcellular location
Nucleoplasm,Plasma membrane

OverviewNCBI Gene

This gene encodes an antigen that is preferentially expressed in human melanomas and that is recognized by cytolytic T lymphocytes. It is not expressed in normal tissues, except testis. The encoded protein acts as a repressor of retinoic acid receptor, and likely confers a growth advantage to cancer cells via this function. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2014]

Canonical amino-acid sequenceUniProt

509 residues, UniProt reviewed canonical sequence.

>P78395|PRAME
     1  MERRRLWGSI QSRYISMSVW TSPRRLVELA GQSLLKDEAL AIAALELLPR ELFPPLFMAA
    61  FDGRHSQTLK AMVQAWPFTC LPLGVLMKGQ HLHLETFKAV LDGLDVLLAQ EVRPRRWKLQ
   121  VLDLRKNSHQ DFWTVWSGNR ASLYSFPEPE AAQPMTKKRK VDGLSTEAEQ PFIPVEVLVD
   181  LFLKEGACDE LFSYLIEKVK RKKNVLRLCC KKLKIFAMPM QDIKMILKMV QLDSIEDLEV
   241  TCTWKLPTLA KFSPYLGQMI NLRRLLLSHI HASSYISPEK EEQYIAQFTS QFLSLQCLQA
   301  LYVDSLFFLR GRLDQLLRHV MNPLETLSIT NCRLSEGDVM HLSQSPSVSQ LSVLSLSGVM
   361  LTDVSPEPLQ ALLERASATL QDLVFDECGI TDDQLLALLP SLSHCSQLTT LSFYGNSISI
   421  SALQSLLQHL IGLSNLTHVL YPVPLESYED IHGTLHLERL AYLHARLREL LCELGRPSMV
   481  WLSANPCPHC GDRTFYDPEP ILCPCFMPN

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PRAME can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.3
Highest tissue expression
102 nTPM

Expression across tissuesHPA

Tissue

  • testis: 102 nTPM
  • epididymis: 9.2 nTPM
  • ovary: 5 nTPM
  • adrenal gland: 3.6 nTPM
  • endometrium: 3.2 nTPM
  • kidney: 1.8 nTPM

Single-cell type

  • differentiating spermatogonia: 41 nCPM
  • early primary spermatocytes: 14 nCPM
  • undifferentiated spermatogonia: 12 nCPM
  • oocytes: 9.2 nCPM
  • late spermatids: 4.7 nCPM
  • sertoli cells: 4 nCPM

Immune cell

  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM
  • MAIT T-cell: 0 nTPM

Brain region

  • white matter: 0.4 nTPM
  • medulla oblongata: 0.3 nTPM
  • pons: 0.3 nTPM
  • hypothalamus: 0.2 nTPM
  • basal ganglia: 0.1 nTPM
  • cerebellum: 0.1 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about PRAME.

Disease | ImmuneIEDB

Conditions an epitope on PRAME was assayed in.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.25
gnomAD pLI
0
gnomAD missense Z
-0.87
DepMap mean gene effect
-0.05
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of PRAME in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PRAME as an antibody target. Whether an autoantibody or antibody against PRAME could matter depends on whether native PRAME is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PRAME is annotated at the cell surface, where native PRAME is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label PRAME as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/PRAME. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...